I can take the first question, but the common drug review people should speak to the provincial matter. I have no knowledge there, and I don't think any of us do. Others can speak to the cancer drugs.
On why we got into the common drug review, previously each department tried to figure out, every time a new drug came on the market, even though it was a lot more expensive, whether it was actually going to provide that much greater benefit for the people to whom we were dispensing the drugs. So we were trying to do it ourselves.
There is not a bottomless pit of resources to do that. It requires a lot of professional expertise—doctors and pharmacists—and they're in high demand. So the view of the partner departments was that rather than each of us trying to build our own drug review process, if we went in it together we could end up getting something that would probably cost less in the long run, we wouldn't be duplicating the same work six times, and it would make it easier for everybody.
So from a user's perspective, that's basically why we got into the common drug review.